Yale Gynecologic Oncology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Wing North Pavilion 1, Suite B
New Haven, CT 06511
- Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion 1, Suite BNew Haven, CT 06511
Gary Altwerger, MD
Gynecologic Oncology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Titles
- Assistant Professor of Obstetrics and Gynecology
- Institutional Review Board Committee Member, Gynecologic Oncology
- Head of Gynecologic Oncology Morbidity and Mortality , Obstetrics, Gynecology & Reproductive Sciences
Education & Training
- FellowshipYale University (2019)
- ResidencyYale University (2016)
- MDUniversity at Buffalo Jacobs School of Medicine and Biomedical Sciences (2012)
- BSState University at Albany, Biochemistry & Molecular Biology (2007)
Additional Information
Honors & Recognitions
- Laxmi Baxi Award for basic and translation research on folic acid receptor in uterine cancer: Society for Reproductive Investigation (2018)
- The John J. Meehan-Clifford R. Miller Award: Yale School of Medicine (2016)
- Resident Teaching Award: Yale School of Medicine (2014)
- Clyde L. Randall Society Award in Gynecology-Obstetrics: Jacobs School of Medicine and Biomedical Sciences (2012)
- Presidential Scholar: University at Albany (2007)
- Phi Beta Kappa: University at Albany (2007)
Publications
- Vlamis C, Abozenah Y, Pebley N, Chang Y, McNamara B, Altwerger G. Laparoscopic pancreatic peritonectomy with splenectomy for recurrent ovarian cancer: a novel approach to achieve R0 while preserving the pancreatic body and tail. International Journal Of Gynecological Cancer 2024, 34: 1474-1475. PMID: 38724238, DOI: 10.1136/ijgc-2024-005358.
- Altwerger G, Ghazarian M, Glazer P. Harnessing the effects of hypoxia-like inhibition on homology-directed DNA repair. Seminars In Cancer Biology 2023, 98: 11-18. PMID: 38029867, PMCID: PMC10872265, DOI: 10.1016/j.semcancer.2023.11.007.
- Abozenah Y, Vlamis C, Ghazarian M, Harold J, Tymon-Rosario J, Altwerger G. Conventional laparoscopic resection of platinum-sensitive recurrent oligometastatic ovarian cancer lesion in the interaortocaval region. International Journal Of Gynecological Cancer 2024, 34: 1651-1652. PMID: 38719278, DOI: 10.1136/ijgc-2024-005269.
- Webster EM, Yadav GS, Gysler S, McNamara B, Black J, Tymon-Rosario J, Zeybek B, Han C, Arkfeld CK, Andikyan V, Menderes G, Huang G, Azodi M, Silasi DA, Santin AD, Schwartz PE, Ratner ES, Altwerger G. Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study. Gynecologic Oncology Reports 2020, 34: 100667. PMID: 33204797, PMCID: PMC7653050, DOI: 10.1016/j.gore.2020.100667.
- Altwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte JF, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancers. Molecular Cancer Therapeutics 2018, 17: molcanther.0930.2017. PMID: 29440294, PMCID: PMC5932245, DOI: 10.1158/1535-7163.mct-17-0930.
- Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancerAltwerger G, Florsheim EB, Menderes G, Black J, Schwab C, Gressel GM, Nelson WK, Carusillo N, Passante T, Huang G, Litkouhi B, Azodi M, Silasi DA, Santin A, Schwartz PE, Ratner ES. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. Journal Of Cancer Research And Clinical Oncology 2018, 144: 2449-2456. PMID: 30255380, DOI: 10.1007/s00432-018-2753-y.
- Altwerger G, Gressel GM, English DP, Nelson WK, Carusillo N, Silasi DA, Azodi M, Santin A, Schwartz PE, Ratner ES. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study. Gynecologic Oncology 2016, 144: 77-82. PMID: 27789084, DOI: 10.1016/j.ygyno.2016.09.027.
- AlAshqar A, Maruthi V, Abi-Raad R, Greenman M, Hui P, Ratner E, Altwerger G, Santin A, Andikyan V. Uterine teratoma and the role of short-tandem repeat genotyping in understanding origins. Gynecologic Oncology Reports 2024, 56: 101652. PMID: 39698441, PMCID: PMC11652878, DOI: 10.1016/j.gore.2024.101652.
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Xu F, Hui P, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses. Gynecologic Oncology 2024, 190: s299-s301. DOI: 10.1016/j.ygyno.2024.07.449.
- C. M, Lavi E, Altwerger G, Lin Z, Ratner E. Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients. PLOS ONE 2024, 19: e0305273. PMID: 38976671, PMCID: PMC11230535, DOI: 10.1371/journal.pone.0305273.
- Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMID: 39516558, PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.
- Bellone S, Jeong K, Halle M, Krakstad C, McNamara B, Greenman M, Mutlu L, Demirkiran C, Hartwich T, Yang-Hartwich Y, Zipponi M, Buza N, Hui P, Raspagliesi F, Lopez S, Paolini B, Milione M, Perrone E, Scambia G, Altwerger G, Ravaggi A, Bignotti E, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Quick C, Angioli R, Terranova C, Zaidi S, Nandi S, Alexandrov L, Siegel E, Choi J, Schlessinger J, Santin A. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2321898121. PMID: 38625939, PMCID: PMC11046577, DOI: 10.1073/pnas.2321898121.
- Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.
- Roque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2024, 130: 1073-1073. PMID: 38438590, PMCID: PMC10951353, DOI: 10.1038/s41416-024-02628-4.
- AlAshqar A, Ghazarian M, Webster E, Upadhyay A, Azodi M, Schwartz P, Ratner E, Altwerger G. Surgical and oncologic outcomes in surgically treated women 80 years and older with endometrioid endometrial cancer as a function of their comorbidities. Gynecologic Oncology Reports 2023, 49: 101240. PMID: 37636496, PMCID: PMC10450407, DOI: 10.1016/j.gore.2023.101240.
- Pan Y, Hood A, Ahmad H, Altwerger G. Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations. Annals Of Pharmacotherapy 2023, 57: 1162-1171. PMID: 36651235, PMCID: PMC11062080, DOI: 10.1177/10600280221149136.
Locations
Yale Gynecologic Oncology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Wing North Pavilion 1, Suite B
New Haven, CT 06511
- Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion 1, Suite BNew Haven, CT 06511
Titles
- Assistant Professor of Obstetrics and Gynecology
- Institutional Review Board Committee Member, Gynecologic Oncology
- Head of Gynecologic Oncology Morbidity and Mortality , Obstetrics, Gynecology & Reproductive Sciences
Education & Training
- FellowshipYale University (2019)
- ResidencyYale University (2016)
- MDUniversity at Buffalo Jacobs School of Medicine and Biomedical Sciences (2012)
- BSState University at Albany, Biochemistry & Molecular Biology (2007)
Additional Information
Honors & Recognitions
- Laxmi Baxi Award for basic and translation research on folic acid receptor in uterine cancer: Society for Reproductive Investigation (2018)
- The John J. Meehan-Clifford R. Miller Award: Yale School of Medicine (2016)
- Resident Teaching Award: Yale School of Medicine (2014)
- Clyde L. Randall Society Award in Gynecology-Obstetrics: Jacobs School of Medicine and Biomedical Sciences (2012)
- Presidential Scholar: University at Albany (2007)
- Phi Beta Kappa: University at Albany (2007)
Publications
- Vlamis C, Abozenah Y, Pebley N, Chang Y, McNamara B, Altwerger G. Laparoscopic pancreatic peritonectomy with splenectomy for recurrent ovarian cancer: a novel approach to achieve R0 while preserving the pancreatic body and tail. International Journal Of Gynecological Cancer 2024, 34: 1474-1475. PMID: 38724238, DOI: 10.1136/ijgc-2024-005358.
- Altwerger G, Ghazarian M, Glazer P. Harnessing the effects of hypoxia-like inhibition on homology-directed DNA repair. Seminars In Cancer Biology 2023, 98: 11-18. PMID: 38029867, PMCID: PMC10872265, DOI: 10.1016/j.semcancer.2023.11.007.
- Abozenah Y, Vlamis C, Ghazarian M, Harold J, Tymon-Rosario J, Altwerger G. Conventional laparoscopic resection of platinum-sensitive recurrent oligometastatic ovarian cancer lesion in the interaortocaval region. International Journal Of Gynecological Cancer 2024, 34: 1651-1652. PMID: 38719278, DOI: 10.1136/ijgc-2024-005269.
- Webster EM, Yadav GS, Gysler S, McNamara B, Black J, Tymon-Rosario J, Zeybek B, Han C, Arkfeld CK, Andikyan V, Menderes G, Huang G, Azodi M, Silasi DA, Santin AD, Schwartz PE, Ratner ES, Altwerger G. Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study. Gynecologic Oncology Reports 2020, 34: 100667. PMID: 33204797, PMCID: PMC7653050, DOI: 10.1016/j.gore.2020.100667.
- Altwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte JF, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancers. Molecular Cancer Therapeutics 2018, 17: molcanther.0930.2017. PMID: 29440294, PMCID: PMC5932245, DOI: 10.1158/1535-7163.mct-17-0930.
- Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancerAltwerger G, Florsheim EB, Menderes G, Black J, Schwab C, Gressel GM, Nelson WK, Carusillo N, Passante T, Huang G, Litkouhi B, Azodi M, Silasi DA, Santin A, Schwartz PE, Ratner ES. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. Journal Of Cancer Research And Clinical Oncology 2018, 144: 2449-2456. PMID: 30255380, DOI: 10.1007/s00432-018-2753-y.
- Altwerger G, Gressel GM, English DP, Nelson WK, Carusillo N, Silasi DA, Azodi M, Santin A, Schwartz PE, Ratner ES. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study. Gynecologic Oncology 2016, 144: 77-82. PMID: 27789084, DOI: 10.1016/j.ygyno.2016.09.027.
- AlAshqar A, Maruthi V, Abi-Raad R, Greenman M, Hui P, Ratner E, Altwerger G, Santin A, Andikyan V. Uterine teratoma and the role of short-tandem repeat genotyping in understanding origins. Gynecologic Oncology Reports 2024, 56: 101652. PMID: 39698441, PMCID: PMC11652878, DOI: 10.1016/j.gore.2024.101652.
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Xu F, Hui P, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses. Gynecologic Oncology 2024, 190: s299-s301. DOI: 10.1016/j.ygyno.2024.07.449.
- C. M, Lavi E, Altwerger G, Lin Z, Ratner E. Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients. PLOS ONE 2024, 19: e0305273. PMID: 38976671, PMCID: PMC11230535, DOI: 10.1371/journal.pone.0305273.
- Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMID: 39516558, PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.
- Bellone S, Jeong K, Halle M, Krakstad C, McNamara B, Greenman M, Mutlu L, Demirkiran C, Hartwich T, Yang-Hartwich Y, Zipponi M, Buza N, Hui P, Raspagliesi F, Lopez S, Paolini B, Milione M, Perrone E, Scambia G, Altwerger G, Ravaggi A, Bignotti E, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Quick C, Angioli R, Terranova C, Zaidi S, Nandi S, Alexandrov L, Siegel E, Choi J, Schlessinger J, Santin A. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2321898121. PMID: 38625939, PMCID: PMC11046577, DOI: 10.1073/pnas.2321898121.
- Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.
- Roque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2024, 130: 1073-1073. PMID: 38438590, PMCID: PMC10951353, DOI: 10.1038/s41416-024-02628-4.
- AlAshqar A, Ghazarian M, Webster E, Upadhyay A, Azodi M, Schwartz P, Ratner E, Altwerger G. Surgical and oncologic outcomes in surgically treated women 80 years and older with endometrioid endometrial cancer as a function of their comorbidities. Gynecologic Oncology Reports 2023, 49: 101240. PMID: 37636496, PMCID: PMC10450407, DOI: 10.1016/j.gore.2023.101240.
- Pan Y, Hood A, Ahmad H, Altwerger G. Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations. Annals Of Pharmacotherapy 2023, 57: 1162-1171. PMID: 36651235, PMCID: PMC11062080, DOI: 10.1177/10600280221149136.
Locations
Yale Gynecologic Oncology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Wing North Pavilion 1, Suite B
New Haven, CT 06511
- Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion 1, Suite BNew Haven, CT 06511
Yale Gynecologic Oncology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Wing North Pavilion 1, Suite B
New Haven, CT 06511
- Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion 1, Suite BNew Haven, CT 06511